Genome Institute of Singapore, Pyrobett to Develop Novel Pyrosequencing Diagnostics | GenomeWeb

NEW YORK (GenomeWeb) – The Genome Institute of Singapore announced today that it has agreed to work with Singapore-based firm Pyrobett to develop novel molecular diagnostics based on pyrosequencing technology.

Pyrobett, which is a joint venture between Qiagen and life sciences instruments manufacturer BMS, has developed a pyrosequencing platform that will be used by the partners in a joint laboratory to create and validate molecular diagnostics assays, including bacterial and viral genotyping, the detection of mutations associated with drug resistance, and cancer detection.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.

Sponsored by
Agilent Technologies

This webinar will discuss a genomic strategy that detects single nucleotide variants and copy number variants in a single assay.

Sponsored by

This webinar will be an interactive roundtable discussion on established and emerging regulatory, scientific, and medical topics related to next-generation sequencing in the clinical setting.